Posted by Michael Wonder on 10 Jul 2022
New drug application for treatment of dry eyes disease submitted to FDA
7 July 2022 - A treatment for dry eye symptoms associated with Meibomian gland dysfunction has been submitted under a new drug application and will be considered by the US FDA.
The application was submitted at the end of last month (June) by the Canada-based global eye health company, Bausch and Lomb Corporation, and German-based Novaliq – a biopharmaceutical company focusing on ocular therapeutics.
